Diffuse Large B-cell Lymphoma Not Otherwise Specified

• CLINICAL_TRIALS research · 2026-04-23
  Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma;…

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma [Phase 2]

  Phase 2 clinical trial evaluating the effectiveness of ViPOR in relapsed/refractory aggressive B-cell lymphomas; the study includes Diffuse …

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas [Phase 2, Phase 3]

  A Phase 2/Phase 3 trial is evaluating adding venetoclax to standard chemotherapy for high-grade B-cell lymphomas, including diffuse large B-…

• CLINICAL_TRIALS research · 2026-03-03
  Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma [Phase 1]

  Phase 1 trial evaluating polatuzumab vedotin with chemotherapy, with or without glofitamab, for untreated aggressive large B-cell lymphoma. …

• CLINICAL_TRIALS research · 2026-02-27
  Clinical Trial Update: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies [Phase 1]

  Poseida Therapeutics is conducting a Phase 1 trial of P-CD19CD20-ALLO1, an allogeneic CAR-T cell therapy, for several B-cell malignancies an…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-01-29
  Clinical Trial Update: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma [Phase 1]

  A Phase 1 trial evaluating the combination of chemotherapy with TAK-659 as front-line treatment for high-risk diffuse large B-cell lymphoma,…

• CLINICAL_TRIALS research · 2024-09-26
  Clinical Trial Update: Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy [Phase 2]

  Phase 2 clinical trial evaluating epcoritamab versus observation in B-cell lymphoma patients not in complete remission after CD19-directed C…

• CLINICAL_TRIALS research · 2024-07-22
  Clinical Trial Update: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL [Phase 2]

  Phase 2 clinical trial evaluating salvage therapy that includes epcoritamab (Epcor) followed by autologous stem cell transplant and epcorita…